Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 18, 2013

Biosearch Moving into New Digs for GMP Production

  • Biosearch Technologies, a company that specializes in the development and manufacture of GMP-grade oligonucleotides, is moving its GMP manufacturing process into a new GMP production facility in Novato, CA, which is also the home of Biosearch's headquarters. The 30,000 square foot facility was developed to further expand processes and controls relevant to medical device and molecular diagnostic customers.

    “The GMP production facility is designed to incorporate the environmental and access controls, linear production flow, and clean room processes critical for the controlled manufacture of highly qualified diagnostic components, reagents, and kits,” said Ron Cook, president and CEO of Biosearch Technologies. “This advanced facility also introduces pharmaceutical-scale lyophilization capabilities allowing for state-of-the-art processing of molecular diagnostic assays in large-scale single batches and all format types.”

    In addition to the relocation to the new facility, Biosearch says it has also successfully completed certification to ISO 13485:2003, meaning that Biosearch has developed, implemented, and maintains a quality management system able to meet the requirements of medical device and molecular diagnostic manufacturing. ISO 13485:2003, according to ISO's website, “specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services.”

    This news comes nearly two months after Biosearch acquired the oligonucleotide manufacturing division of DNA Technology and controlled-pore glass manufacturer VitraBio. Biosearch said the deal reflected its growing commitment to Europe’s biotechnology and diagnostic markets.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »